These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35845580)

  • 1. Comparative Analysis of Clinical Effects of Insulin Aspart Combined with Acarbose and Metformin in the Treatment of Diabetes Mellitus.
    Jin H; Zhang H
    Evid Based Complement Alternat Med; 2022; 2022():3541931. PubMed ID: 35845580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose and siglitine on blood glucose fluctuation and islet β-cell function in patients with type 2 diabetes mellitus.
    Wang RR; Lv ZM; Dan YP; Chen KY; Zhang C
    J Biol Regul Homeost Agents; 2019; 33(2):365-374. PubMed ID: 30972995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching from glargine+insulin aspart to glargine+insulin aspart 30 before breakfast combined with exercise after dinner and dividing meals for the treatment of type 2 diabetes patients with poor glucose control - a prospective cohort study.
    Li J; Wang L; Chen F; Xia D; Miao L
    BMC Endocr Disord; 2018 Oct; 18(1):69. PubMed ID: 30285711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improvement in blood glucose fluctuations of insulin-treated type 1 diabetic patients with additional use of acarbose and assessed by continuous blood glucose monitoring program].
    Ma YR; Xu YC; Ge JP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):854-6. PubMed ID: 22967344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
    Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
    Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin combined with insulin aspart for ameliorating blood glucose levels and maternal and neonatal outcomes in women with gestational diabetes mellitus and chronic hypertension.
    Wang W; Fan Y; Lin Q
    Am J Transl Res; 2021; 13(5):5596-5602. PubMed ID: 34150163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study.
    Du G; Xie W; Su Y; Ma Y; Gao X; Jiang S; Liang H
    PeerJ; 2020; 8():e9905. PubMed ID: 33072435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
    Chen X; Xu Y; Zhang J; Shao S; Duan Y; Liu P; Shen L; Zhang J; Zeng J; Lin M; Zhao S; Ma J; Zhao T; Hu J; Liao Y; Chen X; Hu S; Xue Y; Zeng Z; He W; Liu Z; Li W; Liu L; Yin P; Yu X
    Endocr Pract; 2021 Aug; 27(8):790-797. PubMed ID: 33831552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial.
    Bowering K; Case C; Harvey J; Reeves M; Sampson M; Strzinek R; Bretler DM; Bang RB; Bode BW
    Diabetes Care; 2017 Jul; 40(7):951-957. PubMed ID: 28483786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
    BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Blood Glucose Variability Between Exenatide and Biphasic Insulin Aspart 30 in Chinese Participants with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A Multicenter, Open-Label, Randomized Trial.
    Wang L; Liu X; Yang W; Lai J; Yu X; Liu J; Gao X; Ming J; Ma K; Xu J; Tian Z; He Q; Ji Q
    Diabetes Ther; 2020 Oct; 11(10):2313-2328. PubMed ID: 32856226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus.
    Wu H; Liu J; Lou Q; Liu J; Shen L; Zhang M; Lv X; Gu M; Guo X
    Medicine (Baltimore); 2017 Sep; 96(35):e7533. PubMed ID: 28858080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
    Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E
    Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison on the efficacy of biphasic insulin aspart 30 and premixed human insulin 30/70 through continuous glucose monitoring system].
    Chen SF; Li H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2011 Aug; 32(8):827-9. PubMed ID: 22093477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The comparison of insulin aspart and human soluble insulin used in insulin pump therapy in newly diagnosed type 2 diabetic patients].
    Li YB; Liu J; Liao ZH; Liao Y; Deng WP; Weng JP
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2472-6. PubMed ID: 16321271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
    Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
    Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin aspart and metformin on gestational diabetes mellitus and inflammatory markers.
    Wang Y; Song M; Qi BR
    World J Diabetes; 2023 Oct; 14(10):1532-1540. PubMed ID: 37970132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved pregnancy outcome in gestational diabetes mellitus patients treated with insulin aspart and metformin: a comparative study.
    Fan X; Wang C; Chen L; Zhao X; Wu Y; Zeng G
    Am J Transl Res; 2024; 16(4):1177-1187. PubMed ID: 38715802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.